Johnson & Johnson (JNJ) Tops Q1 EPS by 6c, Updates FY Guidance
Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $2.67, $0.06 better than the analyst estimate of $2.61. Revenue for the quarter came in at $23.4 billion versus the consensus estimate of $23.67 billion.
GUIDANCE:
Johnson & Johnson sees 2022 EPS of $10.15-$10.35, versus the consensus of $10.52. Johnson & Johnson sees 2022 revenue of $94.8-95.8 billion, versus the consensus of $99.48 billion.
Please note that the Company has suspended guidance on its COVID-19 Vaccine sales. The table below excludes COVID-19 Vaccine sales from Adjusted Operational Sales, Operational Sales, and Estimated Reported Sales.
($ in Billions, except EPS) | April 2022 | January 2022 |
Adjusted Operational Sales1,2,5 Change vs. Prior Year | 6.5% – 7.5% | 6.5% – 7.5% |
Operational Sales2,5 Change vs. Prior Year | $97.3B – $98.3B 6.5% – 7.5% | $97.3B – $98.3B 6.5% – 7.5% |
Estimated Reported Sales3,5 Change vs. Prior Year | $94.8B – $95.8B 3.8% – 4.8% | $95.9B - $96.9B 5.0% – 6.0% |
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year | $10.60 - $10.80 8.2% – 10.2% | $10.60 - $10.80 8.2% – 10.2% |
Adjusted EPS (Diluted)3,4 Change vs. Prior Year | $10.15 - $10.35 3.6% – 5.6% | $10.40 - $10.60 6.1% – 8.2% |
1 | Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures |
2 | Non-GAAP financial measure; excludes the impact of translational currency |
3 | Calculated using Euro Average Rate: January 2022 = $1.14 and April = $1.09 (Illustrative purposes only) |
4 | Non-GAAP financial measure; excludes intangible amortization expense and special items |
5 | Excludes COVID-19 Vaccine |
Note: percentages may have been rounded |
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.